Keyphrases
Acute Lymphoblastic Leukemia
66%
Affymetrix
9%
Bone Marrow Relapse
9%
Cancer Causes
6%
Cancer Mortality
6%
Chemotherapy Regimen
6%
Childhood Acute Lymphoblastic Leukemia
100%
Childhood Cancer
6%
Children's Oncology Group
48%
ChIP-seq Analysis
9%
Clinical Testing
6%
Clinical Trials
12%
Conventional Chemotherapy
12%
Current Therapies
6%
Current Treatment
6%
Early Response
9%
Gene Expression Profile
6%
Genome Analysis
6%
Genotype
6%
Health Relevance
6%
High Risk
6%
High-risk Acute Leukemia
18%
Induction Chemotherapy
9%
Induction Therapy
9%
Janus Kinase
9%
Janus Kinase Inhibitors
9%
Kinase Inhibitor Therapy
9%
Kinase mutation
9%
Late Effects
6%
Leukaemia Trials
9%
Leukemia
12%
Modern Threats
9%
Molecular Targeted Agents
9%
Molecular Targeted Therapy
9%
New Drug Targets
6%
On-state Current
6%
Pathway Alteration
9%
Patient's Will
6%
Ph+ Acute Lymphoblastic Leukemia
9%
Philadelphia Chromosome
9%
Population-based
6%
Precursor B-cell Acute Lymphoblastic Leukemia
9%
Public Health
6%
Putative Drug Targets
6%
Relapse Risk
9%
Risk Stratification
6%
Single nucleotide Polymorphism chip
9%
Standard Risk
9%
Targeted Therapy
66%
Therapeutically Applicable Research to Generate Effective Treatments
18%
Ultra-high Risk
9%
Working Diagnosis
18%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
66%
Clinical Trial
7%
Induction Chemotherapy
5%
Janus Kinase
5%
Janus Kinase Inhibitor
5%
Leukemia
7%
Molecularly Targeted Therapy
5%
Oncology
29%
Philadelphia 1 Chromosome
5%
Targeted Therapy
66%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Chemotherapy
7%
Clinical Trial
7%
Janus Kinase
5%
Janus Kinase Inhibitor
5%
Leukemia
7%
Philadelphia 1 Chromosome
5%